奥美拉唑联合生长抑素治疗重症胰腺炎的临床疗效观察

目的：探讨重症胰腺炎患者应用奥美拉唑联合生长抑素治疗的临床效果。方法：选择2010年1月-2012年12月本院收治的86例重症胰腺炎患者作为观察对象,随机将患者分为观察组和对照组,每组各43例,对照组行常规治疗,观察组在此基础上加用奥美拉唑联合生长抑素,疗程7 d,比较两组患者的临床疗效、各项指标恢复时间和并发症发生情况等。结果：观察组有效率93.0%（40/43）,显著高于对照组72.1%（31/43）,两组比较差异具有统计学意义（P〈0.05）;观察组住院时间、肠道恢复时间、腹痛腹胀缓解时间、血尿淀粉酶、等指标恢复至正常时间及并发症发生率均显著低于对照组,差异具有统计学意义（P〈0.05）;观察组死亡率也低于对照组,但差异无统计学意义（P〉0.05）。结论：奥美拉唑联合生长抑素治疗重症胰腺炎患者有效率高,症状改善明显,缩短治疗时间,并发症少,死亡率低,值得临床推广应用。

Observation on the Clinical Curative Effect of Omeprazole Combined with Somatostatin in the Treatment of Severe Acute Pancreatitis

Objective： To investigate the clinical effect of omeprazole combined with somatostatin in the treatment of severe acute pancreatitis. Method： Chosed 86 patients with severe acute pancreatitis from January 2010 to December 2012 in our hospital as research object, patients were randomly divided into observation group and control group, 43 cases in each group, control group received routine therapy, observation group based on control group, combined omeprazole with somatostatin, treatment period was 7 days, the clinical curative effects, recovery time and complications were compared between two groups. Result： The effective rate in observatipn group was 93.0% （ 40/43 ）, significantly higher than 72.1% （ 31/43 ） in control group, had statistically significant differences between two groups （ P〈0.05 ） ; hospitalization time, intestinal recovery time, abdominal pain relief time, blood amylase, urine amylase were restored to normal time and the incidence of complications in observation group were significantly lower than that of control group, the difference was significant （ P〈0.05 ） ; and the mortality in observation group was significantly lower than those in control group, but the differences had no statistically significant （P〉0.05） . Conclusion： Omeprazole combined with somatostatin in the treatment of severe acute pancreatitis patients with high effective rate, symptoms improved significantly, shorten treatment time, less complications, low mortality, it is worthy of clinical application.